Broad global portfolio across diverse markets
Our family of more than 650 compounds, available in thousands of strengths and dosage forms, makes us a leader in key markets.
High-quality global manufacturing footprint and efficient operations
We have an extensive and well-established manufacturing footprint. We operate 29 facilities in 11 countries, across the US, Europe and the MENA, 12 of which are approved by the US FDA and nine by the EU. The strategic investment we have made in our manufacturing capabilities and capacity has created a strong competitive advantage and enabled us to capture significant market opportunities. Quality defines everything we do and we ensure it is delivered consistently worldwide. Our excellent track record of regulatory compliance has made us a trusted partner to our customers and patients.
Established commercial capabilities
We operate across the US, MENA and Europe. In each market, we have experienced teams with local expertise, enabling us to capitalise on opportunities, and navigate challenges. In the US, we have strengthened our management team to ensure that our business is able to respond to the challenging market conditions of 2017. Our strong commercial teams are working to drive maximum value from the products we currently market. At the same time, we are successfully reducing our cost base and we continue to identify opportunities for further savings. While we are focused on navigating near-term headwinds, we are also investing in the future.
Specialised R&D teams and a large, differentiated pipeline
Through increased investment and strategic acquisitions, we have strengthened our R&D capabilities to support sustainable long-term growth. We have dedicated and experienced R&D teams, with the ability to execute and replenish our large and growing product pipeline. We have close to 224 compounds pending approval from global regulatory authorities and approximately 147 compounds under active development. We have the expertise and resources to focus on more differentiated and complex products across a range of therapeutic categories, dosage forms and delivery systems.
Experienced leadership and a strong financial position
Our experienced management teams have a history of growing the business. They have delivered growth whilst ensuring, through a balance of organic growth and acquisitions, that we have maintained a strong balance sheet. In the current challenging environment, this has given our business stability and financial flexibility.
We continue to set ambitious targets for future growth, which will continue to be delivered through organic growth and further strategic acquisitions.
Diversified business model
Our business model is diversified across business segments, regions and products, providing both opportunities and resilience during challenging times.